Orthocell Ltd Total Assets
Orthocell Ltd total assets. Based on the latest financial reports, Orthocell Ltd (OCC) holds total assets worth AU$35.24 Million AUD (≈ $24.93 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see OCC market cap for the company's overall valuation and market capitalisation.
Total Assets of Orthocell Ltd (2010–2025)
Total assets of Orthocell Ltd from 2010 to 2025. This chart illustrates how Orthocell Ltd's total assets have evolved over time, based on quarterly financial data. See Orthocell Ltd stock quote for real-time trading data and today's change.
Orthocell Ltd - Asset Composition Analysis
Orthocell Ltd Total Assets Breakdown (June 2025)
Orthocell Ltd total assets breakdown as of June 2025. Orthocell Ltd's total assets of AU$35.24 Million consist of 90.3% current assets and 9.7% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$26.50 Million | 81.2% |
| Accounts Receivable | AU$1.81 Million | 5.2% |
| Inventory | AU$1.20 Million | 3.4% |
| Property, Plant & Equipment | AU$2.33 Million | 6.6% |
| Intangible Assets | AU$1.07 Million | 3.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Orthocell Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Orthocell Ltd's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Orthocell Ltd's current assets represent 90.3% of total assets in 2025, an increase from 0.0% in 2010.
- Cash Position: Cash and equivalents constituted 81.2% of total assets in 2025, up from 14.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 12.0% in 2010.
- Asset Diversification: The largest asset category is cash and equivalents at 81.2% of total assets.
Orthocell Ltd Competitors by Total Assets
Key competitors of Orthocell Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Orthocell Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.97 | 4.34 | 11.18 |
| Quick Ratio | 4.78 | 4.11 | 11.16 |
| Cash Ratio | 4.47 | 3.89 | 10.99 |
| Working Capital | AU$25.43 Million | AU$17.70 Million | AU$18.94 Million |
Orthocell Ltd - Advanced Valuation Insights
This section examines the relationship between Orthocell Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 17.13 |
| Latest Market Cap to Assets Ratio | 3.11 |
| Asset Growth Rate (YoY) | 32.4% |
| Total Assets | AU$35.24 Million |
| Market Capitalization | $109.42 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Orthocell Ltd's assets at a significant premium (3.11x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Orthocell Ltd's assets grew by 32.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Orthocell Ltd (2010–2025)
The table below shows the annual total assets of Orthocell Ltd from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$35.24 Million ≈ $24.93 Million |
+32.39% |
| 2024-06-30 | AU$26.62 Million ≈ $18.83 Million |
-10.10% |
| 2023-06-30 | AU$29.61 Million ≈ $20.95 Million |
-21.88% |
| 2022-06-30 | AU$37.90 Million ≈ $26.81 Million |
+96.04% |
| 2021-06-30 | AU$19.33 Million ≈ $13.68 Million |
-16.57% |
| 2020-06-30 | AU$23.17 Million ≈ $16.39 Million |
+70.40% |
| 2019-06-30 | AU$13.60 Million ≈ $9.62 Million |
+160.00% |
| 2018-06-30 | AU$5.23 Million ≈ $3.70 Million |
-26.95% |
| 2017-06-30 | AU$7.16 Million ≈ $5.07 Million |
+0.64% |
| 2016-06-30 | AU$7.11 Million ≈ $5.03 Million |
+8.83% |
| 2015-06-30 | AU$6.54 Million ≈ $4.62 Million |
+27.21% |
| 2014-06-30 | AU$5.14 Million ≈ $3.64 Million |
+191.10% |
| 2013-06-30 | AU$1.76 Million ≈ $1.25 Million |
-7.54% |
| 2011-06-30 | AU$1.91 Million ≈ $1.35 Million |
+25.84% |
| 2010-06-30 | AU$1.52 Million ≈ $1.07 Million |
-- |
About Orthocell Ltd
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membr… Read more